Research progress on chemokine receptor 5-targeted therapy for HIV-1.
- Author:
Yan-Jie WANG
;
Jan-Qiong ZHANG
- Publication Type:Journal Article
- MeSH:
CCR5 Receptor Antagonists;
HIV Infections;
drug therapy;
genetics;
metabolism;
pathology;
HIV-1;
drug effects;
Humans;
Molecular Targeted Therapy;
methods;
Receptors, CCR5;
deficiency;
genetics;
metabolism
- From:
Chinese Journal of Virology
2014;30(1):79-83
- CountryChina
- Language:Chinese
-
Abstract:
Along with the spread of human immunodeficiency virus 1 (HIV-1) infection in the world and the emergence of drug-resistant viral strains, it is urgent to seek the novel potent therapies. Chemokine receptor 5 (CCR5) is one of the main coreceptors involved in the entry of HIV-1 into target cells. Nowadays, a number of CCR5 antagonists have been developed and some of them have progressed to clinical trials or been approved. Research progress has also been made in the CCR5-targeted gene therapy. This review summarizes the recent research progress on the CCR5-targeted drug and gene therapy.
